1-5 of 5
Rajasubramaniam Shanmugam, PhD.
Close
Sort by
Journal Articles

International Multi-Site Clinical Validation of Point-of-Care Microchip Electrophoresis Test for Hemoglobin Variant Identification

Arwa Fraiwan, PhD, Muhammad Noman Hasan, MS, Ran An, PhD, Julia Z. Xu, MD MSc, Amy J. Rezac, Nicholas J. Kocmich, Tolulope Oginni, BS, Grace Mfon Olanipekun, Fatimah Hassan-Hanga, MD, Binta W. Jibir, MBBS MPH, Safiya Gambo, MBBS, Anil K. Verma, Praveen K. Bharti, Suchada Riolueang, MSc, Takdanai Ngimhung, Thidarat Suksangpleng, PhD, Priyaleela Thota, MD, Rajasubramaniam Shanmugam, PhD, Aparup Das, PhD, Vip Viprakasit, MD DPhil, Connie M. Piccone, MD, Jane A. Little, MD, Stephen K. Obaro, MD PhD, Umut A. Gurkan, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3373.
https://doi.org/10.1182/blood-2019-129336
Published: 2019
Journal Articles

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined FlĪ²3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

Sravanti Rangaraju, MBBS, Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Larry D Cripe, MD, Katie J Sargent, RN, G. David Roodman, MD PhD, Hamid Sayar, MD MSc, Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Rajasubramaniam Shanmugam, PhD, Adriana Rogozea, Heiko Konig, MD PhD, Reuben Kapur, PhD, H. Scott Boswell, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3949.
https://doi.org/10.1182/blood-2018-99-111181
Published: 2018
Journal Articles

Cyclic Administration of Combination of Sorafenib and Vorinostat In Poor-Risk AML: A Pharmacodynamically-Oriented Extended Phase I Trial

Hamid Sayar, MD, Larry Cripe, MD, Mary Cangany, Jill Weisenbach, RN, OCN, Katie J. Sargent, RN, Chirayu Goswami, PhD., Lang Li, PhD., Annique Wilson-Weekes, MS, Rajasubramaniam Shanmugam, PhD, H. Scott Boswell, MD
Journal: Blood
Blood (2010) 116 (21): 3272.
https://doi.org/10.1182/blood.V116.21.3272.3272
Published: 2010
Journal Articles

Transcriptional Repression of DAPK1 Characterizes a Resistant Phenotype of AML Enforced by Flt3 Signaling and Exclusive Nuclear Abundance of Non-Canonical NFkB2/p52: Synergistic Activity for Flt3 Inhibition along with HDAC Inhibition, or by NFkB Inhibition, for Potentiating ER Stress Apoptosis.

Rajasubramaniam Shanmugam, PhD., Annique Wilson-Weekes, MS, Hamid Sayar, MD, Attaya Suvannasankha, MD, Angelo A. Cardoso, MD., PhD, Katie J Sargent, RN, Larry D. Cripe, MD, Dhananjaya V Kalvakolanu, PhD., H. Scott Boswell, MD
Journal: Blood
Blood (2009) 114 (22): 2387.
https://doi.org/10.1182/blood.V114.22.2387.2387
Published: 2009
Journal Articles

The Sesquiterpene Lactone Parthenolide Induces Apoptosis and Overcomes the Protective Effect of the Bone Marrow Microenvironment in Human Multiple Myeloma Cells.

Attaya Suvannasankha, MD, Colin D. Crean, Rajasubramaniam Shanmugam, PhD, Rafat Abonour, MD, H. Scott Boswell, MD, Harikrishna Nakshatri, PhD
Journal: Blood
Blood (2006) 108 (11): 5058.
https://doi.org/10.1182/blood.V108.11.5058.5058
Published: 2006